Pentabase

Executive Summary

Pentabase is a Danish biotechnology company established in 2006 that focuses on molecular diagnostics, leveraging its proprietary INA® (Intercalating Nucleic Acid) technology to develop highly sensitive PCR assays. The company's platform enables accurate detection of cancer biomarkers and patient monitoring, addressing critical needs in oncology. Pentabase offers a range of CE-IVD marked diagnostic kits and custom oligonucleotides for both research and clinical applications, positioning itself as a specialized supplier in the precision diagnostics space. Despite being privately held with limited public financial data, the company's long-standing presence and technological niche suggest a steady, albeit niche, market role. Pentabase's strengths lie in its robust assay sensitivity and the flexibility to tailor products for specific diagnostic requirements, which may appeal to hospitals, laboratories, and pharmaceutical partners looking for reliable molecular tools.

Upcoming Catalysts (preview)

• Q4 2026Launch of new liquid biopsy assay for early cancer detection70% success
• Q2 2027FDA submission for a lead cancer diagnostic product50% success
• Q3 2026Strategic partnership with a pharmaceutical company for companion diagnostics60% success